Research explained

Cannabis hyperemesis syndrome: why emergency visits for severe vomiting have risen

Cannabis hyperemesis syndrome (CHS) causes bouts of severe nausea and vomiting in some people who use cannabis often, usually for a long time. Emergency visits for CHS rose in the US and Canada over the past decade. Studies link the rise to more frequent use, bigger cannabis markets and the COVID-19 pandemic, and to doctors spotting CHS more often. Reviews find that stopping cannabis appears to be the best treatment.

Checked against the CDC's MMWR report on CHS, the CDC/NCHS ICD-10-CM code files and the peer-reviewed studies listed below on . Next review: .

Short answer: CHS causes repeated bouts of severe nausea, vomiting and belly pain in some people who use cannabis often.1 Studies in the US and Canada found that emergency room (ER) visits for CHS rose many times over from the mid-2010s, with a big jump in 2020.34 Part of the rise may be real, and part may come from doctors getting better at spotting and recording CHS.1 Reviews find that stopping cannabis appears to be the best treatment.89

Call 911 if someone who has been vomiting passes out, becomes confused or has a seizure.13 See emergency help.

What CHS is

CHS is a condition linked to using cannabis often over a long time. It causes sudden bouts of severe nausea, vomiting and belly pain. Symptoms can be severe enough that people seek medical care.1 Doctors first described CHS in 2004, in Australia.4

A review published in 2016 pooled 183 articles and case reports about CHS. These features came up most often:8

  • Bouts of nausea and vomiting that come and go (100% of cases)
  • Using cannabis at least once a week (97%)
  • Symptoms going away after the person stopped using cannabis (97%)
  • Taking hot baths or showers again and again, because the heat brings relief (92%)
  • Belly pain (85%)

These numbers pool published reports, including case reports about single patients. They show what doctors noticed, not how common each sign is in everyone with CHS.8

CHS can seem surprising. Medicines made from THC-like compounds have been used since 1985 to treat nausea from cancer treatment.5 Doctors often mistake CHS for a different condition, cyclic vomiting syndrome.1

A new diagnosis code

Until recently, US doctors had no code of their own for CHS. On October 1, 2025, a new code took effect: R11.16, “Cannabis hyperemesis syndrome.”12 Before that, researchers had to estimate CHS cases from a code for vomiting plus a code for cannabis use.13 That matters when you read the numbers below.

What the studies found

Most studies count ER visits as a rate, such as visits “per 100,000 people” or “per 100,000 ER visits.” A rate lets you compare years even when the number of people or visits changes.

Ontario, Canada (2014 to 2021)

This study counted ER visits for CHS among everyone aged 15 and older in Ontario. The monthly rate rose 13-fold, from 0.26 to 3.43 visits per 100,000 people, between January 2014 and June 2021. In all, there were 12,866 visits by 8,140 people.3

  • Visits were already rising before cannabis became legal in October 2018. Legalization itself was not linked to a change.3
  • In 2020, Ontario let many more stores open and allowed new products, such as edibles and concentrates. Right after that, the visit rate jumped by about half (49%).3
  • The COVID-19 pandemic started at the same time, so the study cannot fully separate the two.3
  • About 1 in 11 visits (8.8%) led to a hospital stay. The share of people who came back to the ER for CHS within 6 months rose from 12.8% before legalization to 21.9% in 2020 and 2021.3

United States (2016 to 2022)

This study used a large national sample of ER visits. CHS visits rose from 4.4 per 100,000 ER visits in 2016 to a peak of 33.1 in spring 2020. In 2022, the rate was still 22.3 per 100,000 ER visits, about five times the 2016 rate.4

Northern California (2009 to 2019)

This study looked at adult members of Kaiser Permanente Northern California. The share of adults with an ER visit for suspected CHS rose 175%, from about 16 to about 44 per 10,000 adults, between 2009 and 2019. Yearly ER visits for suspected CHS rose from 4,142 to 16,795.5 The rate peaked in 2017 and then leveled off. Legal adult-use sales in California started in January 2018, so most of this rise came before those sales began.5

Nevada (2013 to 2021)

ER visits for CHS in Nevada roughly doubled, from 1.07 to 2.22 per 100,000, after recreational cannabis sales began in mid-2017.7

Teens and young adults (2016 to 2023)

This study looked at 13- to 21-year-olds at US children’s hospitals. ER visits for CHS rose more than 10-fold, from about 160 to about 1,968 per 1 million ER visits. Visits rose in states with legal recreational sales and in states without them. Rates were higher in states with legal sales.6

The new code, nationwide (2023 to 2026)

A CDC report looked at about 3,600 US emergency departments. From January 2023 to September 2025, CHS made up a steady share of about 3 in every 10,000 ER visits. In October 2025, the month the new code started, that share jumped to about 11 in every 10,000. From October 2025 to May 2026, the monthly average was 3.7 times as high as before.1

CDC says this sudden jump likely reflects, at least in part, better recognition and coding of CHS, not a sudden real rise in cases. It also suggests that earlier counts missed many cases.1

Why have visits gone up?

No study proves a single cause. Researchers point to several likely reasons:

  • More frequent use. More people report using cannabis daily or near daily.1
  • Stronger products. THC levels in cannabis products have gone up over time. THC strength has not been directly linked to CHS. But stronger products are linked to more frequent use, which is the main risk factor.1
  • Bigger markets. In Ontario and Nevada, visits rose after more stores and products became available.37
  • The pandemic. Visits jumped in 2020 in both the US and Ontario.34
  • Better recognition. Doctors may be more aware of CHS, and people may be more willing to say they use cannabis. The new code also makes CHS easier to count.13

Legal sales are not the whole story. Among teens, visits also rose in states without legal recreational sales.6

Who is at risk

  • People who use cannabis often. Frequent use is the main risk factor for CHS.1 One review found symptoms began after 6 months to 11 years of use.9 Newer evidence suggests symptoms can start within the first year of use.1
  • Teens and young adults. In the national 2016 to 2022 study, risk was highest at ages 18 to 25.4 In CDC’s data, the share of ER visits involving CHS was highest at ages 15 to 24.1 In Ontario, the average age was 27.3
  • Men and women. Results differ by study. CDC found higher shares among women and girls.1 The national 2016 to 2022 study found slightly lower risk in women.4 In Ontario, about half of people with a CHS visit were women.3

Not everyone who uses cannabis often gets CHS. No one yet knows why some people do and others do not.5

What helps

Stopping cannabis

Reviews find that stopping cannabis appears to be the best treatment.89 In the published case reports, symptoms went away after stopping in almost every case where this was recorded.8

If you want help cutting back or stopping, you can call SAMHSA’s National Helpline at 1-800-662-4357 (1-800-662-HELP). It is free, confidential and open 24 hours a day, every day, in English and Spanish. It can refer you to treatment and support groups near you.14

Hot showers or baths

Many people with CHS find that hot showers or baths ease their symptoms for a while.89 This may bring relief, but the reviews still point to stopping cannabis as the best treatment.9

Care in the emergency room

ER care for CHS often includes fluids through a vein (IV) and treatment for dehydration and problems with blood salts (electrolytes).58 Some treatments have been studied, but only in small studies:

  • Haloperidol. In a small trial published in 2020, 30 people with CHS got either haloperidol or ondansetron, a common anti-nausea medicine. Two hours later, the haloperidol group had more relief from pain and nausea. They also left the ER sooner, on average after 3.1 hours instead of 5.6 hours. Two people on the higher dose of haloperidol came back with acute dystonia, a type of muscle spasm.10
  • Capsaicin cream. Capsaicin is the compound that makes chili peppers hot. A 2024 review found 7 studies with 492 patients. Results for capsaicin cream on the skin were mixed. Medicines like haloperidol may help, but the studies were few and small.11
  • Emergency medicine guidance. A 2024 guideline for adults suggests that ER doctors may add haloperidol or droperidol to usual anti-nausea care, and may offer capsaicin cream. The authors rated the evidence for both as “very low certainty.”12

Watch for dehydration

Vomiting makes the body lose fluid, which can lead to dehydration. Severe dehydration is a life-threatening emergency.13 Signs of severe dehydration include:13

  • Not peeing, or very dark yellow pee
  • Dizziness or feeling lightheaded
  • A fast heartbeat or fast breathing
  • Confusion or irritability

Call 911 if the person passes out, becomes confused, has a seizure, or is not getting better or is getting worse despite treatment.13 In rare cases, CHS has led to death.1 For urgent help, see emergency help.

How strong is the evidence?

We rate the evidence on how often CHS sends people to the ER, and its link to frequent cannabis use, as moderate. See how we rate evidence.

  • What makes it stronger: Large studies in different places, using different data, all found that ER visits for CHS went up.134567
  • What makes it weaker: Before October 2025 there was no CHS code, so researchers had to estimate cases from other codes. Some cases were likely missed, and some visits may have been counted by mistake.134 These studies show patterns over time. They cannot prove what caused the rise.3

The evidence on treatments in the ER is limited: a few small studies, and guideline authors rated it “very low certainty.”1112 The finding that stopping cannabis helps comes mainly from case reports and reviews, not from controlled trials. But it is consistent across those reports.89

What we still don’t know

  • What causes CHS in the body. The reason cannabis triggers vomiting in some people is still unclear.8
  • Why only some people get it. It is not known why CHS happens in some people who use cannabis often but not in others.5
  • Whether stronger products raise the risk directly. CDC says more tracking is needed to understand the role of high-THC products and hemp-derived products.1
  • How common CHS really is. ER data miss people who never go to the ER, so they likely undercount CHS.1
  • The best ER treatment. Larger, well-designed trials are needed.11
  • How the new code will change the numbers. It will take time to tell real changes in CHS apart from changes in coding.14